Lv1
80 积分 2022-07-05 加入
A Phase I/II Study of [
1天前
求助中
A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol
1个月前
已关闭
Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
1个月前
已关闭
Byproducts in the synthesis of [68Ga]Ga-PSMA-11
1个月前
已完结
Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer
1个月前
已关闭
[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience
2个月前
已完结
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer
2个月前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
2个月前
已完结
Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer
3个月前
已完结
Synthesis of piperazine-based fluorinated fibroblast activation protein inhibitors for the development of a novel 18F-labeled PET imaging probe
3个月前
已完结
皖公网安备34019202002308
